PT20
Our second asset, PT20, is a treatment for hyperphosphatemia that has successfully completed a first pivotal trial. In addition, the Group has earlier stage assets that it intends to develop or out-license over time.
Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. Our most advanced pipeline asset, PT20, has completed its first pivotal study with one further pivotal Phase 3 study planned in order to seek regulatory approval in major markets.
Read more
